1.Clinical Study of a Newly Diagnosed Case of Gitelman Syndrome in a Patient Monitored for Liddle Syndrome.
Jun Hyung PARK ; Hyung Young KIM ; Da Hee KIM ; Ji Won KIM ; Sang Hyun KIM ; Won Do PARK
Soonchunhyang Medical Science 2016;22(2):136-140
A 55-year-old man who had been monitored for Liddle syndrome in the nephrology division for 15 years visited again Inje University Sanggye Paik Hospital for a newly developed electrolyte disorder. Because his blood pressure was normal and he showed hypomagnesemia and hypokalemia, a renal clearance test and renal biopsy were conducted for suspected Gitelman syndrome. The patient was diagnosed with Gitelman syndrome, which has been previously reported 12 cases in South Korea. The renal clearance test revealed a disorder of the Na-Cl cotransporter (NCCT) in the distal tubule, while the renal biopsy revealed partial expression of NCCT, typical of Gitelman syndrome. Currently, the patient is being monitored, and is receiving oral administration of calcium and magnesium.
Administration, Oral
;
Biopsy
;
Blood Pressure
;
Calcium
;
Clinical Study*
;
Gitelman Syndrome*
;
Humans
;
Hypokalemia
;
Korea
;
Liddle Syndrome*
;
Magnesium
;
Middle Aged
;
Nephrology
;
Solute Carrier Family 12, Member 3
2.Nonlinear Reduction in Risk for Type 2 Diabetes by Magnesium Intake: An Updated Meta-Analysis of Prospective Cohort Studies.
Tian XU ; Guo Chong CHEN ; Lin ZHAI ; Kai Fu KE ;
Biomedical and Environmental Sciences 2015;28(7):527-534
Observational studies between magnesium int- ake and risk of type 2 diabetes yielded inconsistent results. We conducted a system literature search of PubMed database through March 2015 for prospective cohort studies of magnesium intake and type 2 diabetes risk. Study-specific results were pooled in a random-effects model. Subgroup and sensitivity analysis were performed to assess the potential sources of heterogeneity and the robustness of the pooled estimation. Generalized least squares trend estimation was used to investigate the dose-response relationship. A total of 15 papers with 19 analyses were identified with 539,735 participants and 25,252 incident diabetes cases. Magnesium intake was associated with a significant lower risk of type 2 diabetes (RR: 0.77; 95% CI: 0.71-0.82) for the highest compared with lowest category. This association was not significantly modified by the pre-specified study characteristics. In the dose-response analysis, a magnesium intake increment of 100 mg/day was associated with a 16% reduction in type 2 diabetes risk (RR: 0.84; 95% CI: 0.80-0.88). A nonlinear relationship existed between magnesium intake and type 2 diabetes (P-nonlinearity=0.003). This meta-analysis further verified a protective effect of magnesium intake on type 2 diabetes in a nonlinear dose-response manner.
Diabetes Mellitus, Type 2
;
epidemiology
;
prevention & control
;
Dose-Response Relationship, Drug
;
Humans
;
Least-Squares Analysis
;
Magnesium
;
administration & dosage
;
blood
;
Nonlinear Dynamics
;
Prospective Studies
;
Risk
3.Efficacy of Magnesium Trihydrate of Ursodeoxycholic Acid and Chenodeoxycholic Acid for Gallstone Dissolution: A Prospective Multicenter Trial.
Jong Jin HYUN ; Hong Sik LEE ; Chang Duck KIM ; Seok Ho DONG ; Seung Ok LEE ; Ji Kon RYU ; Don Haeng LEE ; Seok JEONG ; Tae Nyeun KIM ; Jin LEE ; Dong Hee KOH ; Eun Taek PARK ; Inseok LEE ; Byung Moo YOO ; Jin Hong KIM
Gut and Liver 2015;9(4):547-555
BACKGROUND/AIMS: Cholecystectomy is necessary for the treatment of symptomatic or complicated gallbladder (GB) stones, but oral litholysis with bile acids is an attractive alternative therapeutic option for asymptomatic or mildly symptomatic patients. This study was conducted to evaluate the efficacy of magnesium trihydrate of ursodeoxycholic acid (UDCA) and chenodeoxycholic acid (CDCA) on gallstone dissolution and to investigate improvements in gallstone-related symptoms. METHODS: A prospective, multicenter, phase 4 clinical study to determine the efficacy of orally administered magnesium trihydrate of UDCA and CDCA was performed from January 2011 to June 2013. The inclusion criteria were GB stone diameter < or =15 mm, GB ejection fraction > or =50%, radiolucency on plain X-ray, and asymptomatic/mildly symptomatic patients. The patients were prescribed one capsule of magnesium trihydrate of UDCA and CDCA at breakfast and two capsules at bedtime for 6 months. The dissolution rate, response rate, and change in symptom score were evaluated. RESULTS: A total of 237 subjects were enrolled, and 195 subjects completed the treatment. The dissolution rate was 45.1% and the response rate was 47.2% (92/195) after 6 months of administration of magnesium trihydrate of UDCA and CDCA. Only the stone diameter was significantly associated with the response rate. Both the symptom score and the number of patients with symptoms significantly decreased regardless of stone dissolution. Adverse events necessitating discontinuation of the drug, surgery, or endoscopic management occurred in 2.5% (6/237) of patients. CONCLUSIONS: Magnesium trihydrate of UDCA and CDCA is a well-tolerated bile acid that showed similar efficacy for gallstone dissolution and improvement of gallstone-related symptoms as that shown in previous studies.
Adult
;
Aged
;
Antacids/*administration & dosage
;
Chenodeoxycholic Acid/*administration & dosage
;
Cholagogues and Choleretics/*administration & dosage
;
Drug Administration Schedule
;
Drug Combinations
;
Female
;
Gallstones/*drug therapy
;
Humans
;
Magnesium Hydroxide/*administration & dosage
;
Male
;
Middle Aged
;
Prospective Studies
;
Severity of Illness Index
;
Solubility/drug effects
;
Ursodeoxycholic Acid/*administration & dosage
4.Effect of Magnesium Sulfate, Nifedipine Tablet Combined Salvia Injection on ET-1/NO, TXA2/PGI2 and Hemorheology of Preeclampsia Patients.
Xiao-ying ZHENG ; Jing YAO ; Jia-mei ZHU ; Mei LI ; Shu-qiong QIU ; Zhao-xia ZHU ; Ming ZHANG
Chinese Journal of Integrated Traditional and Western Medicine 2015;35(8):962-965
OBJECTIVETo observe the effect of magnesium sulfate, Nifedipine Tablet (NT) combined Salvia Injection (SI) on endothelin-1 (ET-1), nitric oxide (NO), thromboxane A2(TXA2), prostacyclin I2(PG2), and hemorheology of preeclampsia patients.
METHODSTotally 704 preeclampsia patients were randomly assigned to the treatment group and the control group, 352 cases in each group. All patients were treated with magnesium sulfate combined NT (on the first day: slow intravenous injection of magnesium sulfate 5 g + intravenous dripping of magnesium sulfate injection 10 g + oral administration of NT 30 mg; on the second and third day, intravenous dripping of magnesium sulfate injection 10 g + oral administration of NT 30 mg), while those in the treatment group were dripped with SI additionally at 20 mL per day for 3 consecutive days. Before and after treatment plasma levels of endothelin-1 (ET-1), nitric oxide (NO), TXA2, PGi2, and hemorheology indicators [such as high blood viscosity (HBV), low blood viscosity (LBV), plasma viscosity (PV), erythrocyte rigidity index (ERI), fibrinogen (FIB)] of two groups were detected.
RESULTSCompared with the same group before treatment, serum levels of ET-1, TXA2, HBV, LBV, PV, ERI, and FIB decreased in the two groups after treatment (P <0. 05), but levels of NO and PG2 increased (P <0. 05). Compared with the control group in the same period, levels of ET-1, TXA2, HBV, LBV, PV, ERI, and FIB decreased in the treatment group after treatment (P <0. 05), but levels of NO and PGI2 increased (P <0. 05).
CONCLUSIONMagnesium sulfate, NT combined SI could effectively regulate the balance of ET-1/NO and TXA2/PGI2, and improve hemorheology of preeclampsia patients.
Drug Therapy, Combination ; Drugs, Chinese Herbal ; pharmacology ; therapeutic use ; Endothelin-1 ; metabolism ; Epoprostenol ; metabolism ; Female ; Hemorheology ; Humans ; Injections ; Magnesium Sulfate ; administration & dosage ; pharmacology ; therapeutic use ; Nifedipine ; administration & dosage ; pharmacology ; therapeutic use ; Nitric Oxide ; metabolism ; Pre-Eclampsia ; drug therapy ; Pregnancy ; Salvia ; Tablets ; Thromboxane A2 ; metabolism
5.Effects of transdermal magnesium chloride on quality of life for patients with fibromyalgia: a feasibility study.
Deborah J ENGEN ; Samantha J MCALLISTER ; Mary O WHIPPLE ; Stephen S CHA ; Liza J DION ; Ann VINCENT ; Brent A BAUER ; Dietlind L WAHNER-ROEDLER ; E-mail: WAHNERROEDLER.DIETLIND@MAYO.EDU.
Journal of Integrative Medicine 2015;13(5):306-313
BACKGROUNDFibromyalgia is a syndrome characterized by chronic pain, fatigue, depression, and sleep disturbances. Its primary cause is unclear. Several studies have reported decreased intracellular magnesium levels in patients with fibromyalgia and have found negative correlation between magnesium levels and fibromyalgia symptoms.
OBJECTIVETo gather preliminary data on whether transdermal magnesium can improve quality of life for women who have fibromyalgia.
DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONSThis is a patient questionnaires and survey in a fibromyalgia clinic at a tertiary medical center. Forty female patients with the diagnosis of fibromyalgia were enrolled. Each participant was provided a spray bottle containing a transdermal magnesium chloride solution and asked to apply 4 sprays per limb twice daily for 4 weeks. Participants were asked to complete the Revised Fibromyalgia Impact Questionnaire, SF-36v2 Health Survey, and a quality-of-life analog scale at baseline, week 2, and week 4.
MAIN OUTCOME MEASUREQuestionnaire and survey scores, evaluated through intent-to-treat and per-protocol analyses.
RESULTSTwenty-four patients completed the study (mean [SD] age, 57.2 [7.6] years; white, 95%; mean body mass index, 31.3 kg/m2). With intention-to-treat analysis, Revised Fibromyalgia Impact Questionnaire subscale and total scores were significantly improved at week 2 and week 4 (total score, P=0.001). Per-protocol analysis results were similar: all subscales of the Revised Fibromyalgia Impact Questionnaire were significantly improved at week 2 and week 4 (total score, P=0.001).
CONCLUSIONThis pilot study suggests that transdermal magnesium chloride applied on upper and lower limbs may be beneficial to patients with fibromyalgia.
TRIAL REGISTRATIONClinicalTrials.gov.ldentifier NCT01968772.
Administration, Cutaneous ; Aged ; Feasibility Studies ; Female ; Fibromyalgia ; drug therapy ; psychology ; Humans ; Magnesium Chloride ; administration & dosage ; adverse effects ; Middle Aged ; Pilot Projects ; Quality of Life
6.Ventricular arrhythmia in patients with prolonged QT interval during liver transplantation: two cases report.
Min Soo KIM ; Na Young KIM ; Ji Eun PARK ; Soon Ho NAM
Korean Journal of Anesthesiology 2014;67(6):416-420
QT interval prolongation is associated with an increased risk of ventricular arrhythmia in various conditions. Cardiac electrophysiologic abnormalities including QT interval prolongation are well documented in patients with advanced liver cirrhosis. We report two cases of patients with QT interval prolongation on preoperative electrocardiography who exhibited repetitive ventricular arrhythmias with significant hemodynamic deterioration during liver transplantation. For the treatment and prevention of ventricular arrhythmias during the intraoperative period, we performed intravenous administration of lidocaine and isoproterenol, corrected imbalances of electrolytes including potassium and magnesium, and prepared a defibrillator. These cases emphasize that preoperative recognition of QT interval prolongation and adequate management to prevent fatal arrhythmias are important in patients undergoing liver transplantation.
Administration, Intravenous
;
Arrhythmias, Cardiac*
;
Defibrillators
;
Electrocardiography
;
Electrolytes
;
Hemodynamics
;
Humans
;
Intraoperative Complications
;
Intraoperative Period
;
Isoproterenol
;
Lidocaine
;
Liver Cirrhosis
;
Liver Transplantation*
;
Magnesium
;
Potassium
7.Evaluation of the CS-6400 Automated Chemistry Analyzer.
Hyo Jun AHN ; Hye Ryun KIM ; Young Kyu SUN
Journal of Laboratory Medicine and Quality Assurance 2013;35(1):36-46
BACKGROUND: Analyzing large numbers of specimens in a short time and generating accurate results while minimizing costs are critical to laboratory tests. The CS-6400 (Dong-A Dirui, China), an automated chemistry analyzer, has been recently developed in China in collaboration with domestic corporations. To assess the performance and usability of the analyzer, we evaluated its analytical performance and clinical usefulness including accuracy and linearity of electrolytes and chemistry tests using HiSens reagent (HBI Co., Korea) with protocols provided by the Clinical and Laboratory Standards Institute, and compared these results with those of the formerly used DXC800 (Beckman Coulter, USA), and Vista500 (Siemens, Germany). METHODS: The accuracy, linearity, recovery factor, and sample carryover of the CS-6400 using HiSens reagent were determined for 29 tests-aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), gamma glutamyl transferase, glucose, total cholesterol, triglyceride (TG), amylase, lipase, creatine kinase (CK), blood urea nitrogen, creatinine, uric acid, total protein, albumin, total bilirubin (TB), direct bilirubin (DB), calcium, inorganic phosphorus, magnesium (MG), HDL cholesterol, rheumatoid factor (RF), LDL cholesterol, C-reactive protein, anti-streptolysin O, sodium, potassium, and chloride and the results were compared with the values obtained from the DXC800 and Vista500 to set reference intervals for each test. Serum samples obtained from 128 healthy adults were used for the reference intervals. and values obtained from DXC800 and Vista500 were used to make comparison on and to set reference intervals for each routine. Serum specimens obtained from a total of 128 healthy adults were used for the reference intervals. RESULTS: The coefficient of variation showed excellent values of < or =5% for all tests except ALP, DB, MG, RF, TB, and TG (> or =5%). The coefficient of determination (R2) was > or =0.993 with linearity between 0.928 and 1.078 within the useful clinical span. In addition, the recovery factor values of the tests were 84% to 108%, and correlation comparisons were 0.975 except for albumin (0.9516), RF (0.7617), and LDL cholesterol (0.9709). We evaluated whether the CS-6400 contributed to the attempt to minimize the test's cost and running time. Developed in China, the CS-6400 has been approved by the Food and Drug Administration and uses indirect ion selective electrodes for electrolytes and colorimetry and turbidimetry for general and specific chemistry items. The tests showed excellent linearity of > or =0.993 using commercial certified linearity material. The recovery factor values of the tests were 93% to 108%, except for LDL cholesterol (84%). Except for the minimum values, percentage sample carryover values for CK and LDH were < or =1% (0.00% and 0.07%, respectively), suggesting that the results of the tests were not affected by sample carryover, and reference interval was present based on sex. CONCLUSIONS: The CS-6400 with HiSens showed excellent analytical performance (precision, linearity, and accuracy). Furthermore, results from the CS-6400 were highly correlated with those obtained from similar tests performed on DXC800 and Vista500. Therefore, the CS-6400 is appropriate for tertiary care hospitals where large volumes of test samples must be processed within a short period with minimal cost.
Adult
;
Alanine Transaminase
;
Alkaline Phosphatase
;
Amylases
;
Bilirubin
;
Blood Urea Nitrogen
;
C-Reactive Protein
;
Calcium
;
China
;
Cholesterol
;
Cholesterol, HDL
;
Cholesterol, LDL
;
Colorimetry
;
Cooperative Behavior
;
Creatine Kinase
;
Creatinine
;
Electrolytes
;
Glucose
;
Humans
;
Ion-Selective Electrodes
;
L-Lactate Dehydrogenase
;
Lipase
;
Magnesium
;
Nephelometry and Turbidimetry
;
Phosphorus
;
Potassium
;
Rheumatoid Factor
;
Running
;
Sodium
;
Tertiary Healthcare
;
Transferases
;
United States Food and Drug Administration
;
Uric Acid
8.Echinostome Flukes Receovered from Humans in Khammouane Province, Lao PDR.
Jong Yil CHAI ; Woon Mok SOHN ; Tai Soon YONG ; Keeseon S EOM ; Duk Young MIN ; Eui Hyug HOANG ; Bounlay PHAMMASACK ; Bounnaloth INSISIENGMAY ; Han Jong RIM
The Korean Journal of Parasitology 2012;50(3):269-272
Echinostome eggs were detected in 22 (1.1%) of 2,074 people residing in riparian villages along the Mekong River in Khammouane Province, Lao PDR. In order to recover the adult flukes, 9 persons were treated with praziquantel and purged with magnesium salts. A total of 55 echinostome specimens (4 species) were recovered from the 9 persons. Echinostoma revolutum (8 specimens) was recovered from 3 persons, Artyfechinostomum malayanum (8 specimens) was from 2 persons, Echinochasmus japonicus (33 specimens) was from 7 persons, and Euparyphium sp. (6 specimens) was from 1 person. In Lao PDR, only human infections with E. japonicus were previously known. Therefore, the present study describes human infections with E. revolutum, A. malayanum, and Euparyphium sp. for the first time in Lao PDR. These results indicate that the surveyed villages of Khammouane Province, Lao PDR are low-grade endemic foci of echinostomiasis.
Adult
;
Animals
;
Anthelmintics/administration & dosage
;
Echinostomatidae/*classification/*isolation & purification
;
Female
;
Humans
;
Laos
;
Magnesium/administration & dosage
;
Male
;
Praziquantel/administration & dosage
;
Trematode Infections/*parasitology
9.Clinical re-evaluation of effects of two different "cocktail therapy" to prevent from phlebitis induced by Chansu injection.
Yu-Bin ZHAO ; Zhe HAO ; Hong-Dan ZHANG ; Yan-Ming XIE
China Journal of Chinese Materia Medica 2012;37(18):2739-2741
OBJECTIVETo re-evaluate the effects of different "cocktail therapy" to prevent from phlebitis induced by Chansu injection.
METHODPatients treated with Chansu injection were divided randomLy into 4 groups with 90 per group, control group, phentolaminum group, the magnesium sulfate group-phentolaminum group, and anisodamine-phentolaminum group. Patients in the control group only received the routine nursing treatment, and patients in the various experiment group received different interventions. The comparison was made in the morbidity and the starting time of occurrence of phlebitis, the severity of pain, duration of pain.
RESULTThe morbidity of phlebitis was 8%, 8%, 6%, respectively. The starting time of phlebitis occurrence was (22 +/- 4), (27 +/- 5), (28 +/- 7) h, respectively. The NRS of pain was (4.75 +/- 1.51), (3.27 +/- 1.02), (2.71 +/- 1.63), respectively. The duration time of pain was (4.25 +/- 1.36), (2.51 +/- 1.05), (2.19 +/- 1.13) d respectively. In control group, the morbidity of phlebitis, the starting time of occurrence of phlebitis, the severity of pain, duration of pain was 30%, (16 +/- 4) h, (6.34 +/- 1.21), (5.47 +/- 1.07) d, respectively. As compared with the control group, a significance difference was found between every group in three test groups and control group respectively (P<0.05).
CONCLUSIONThe morbidity and the starting time of occurrence of phlebitis, the severity of pain, duration of pain was significantly reduced respectively by two different "cocktail therapy".
Adult ; Aged ; Animals ; Anura ; Bufanolides ; administration & dosage ; adverse effects ; Drug Therapy, Combination ; Humans ; Magnesium Sulfate ; therapeutic use ; Male ; Middle Aged ; Phentolamine ; therapeutic use ; Phlebitis ; drug therapy ; etiology ; prevention & control ; Solanaceous Alkaloids ; therapeutic use ; Young Adult
10.Clinical re-evaluation of effects of different treatments to prevent from phlebitis induced by Chansu injection.
Yubin ZHAO ; Zhe HAO ; Hongdan ZHANG ; Jian SHI ; Yanming XIE
China Journal of Chinese Materia Medica 2011;36(20):2803-2806
OBJECTIVETo re-evaluate the effects of different treatments to prevent from phlebitis induced by Chansu injection.
METHODPatients treated with Chansu injection were divided randomly into 4 groups with 50 per group, control group, the magnesium sulfate group, phentolaminum group, and anisodamine group. Patients in the control group only received the routine nursing treatment, and patients in the various experiment group received different interventions. The comparison was made in the morbidity and the starting time of occurrence of phlebitis, the severity of pain, duration of pain.
RESULTThe morbidity of phlebitis was 8%, 8%, 6% respectively. The starting time of phlebitis occurrence was (21 +/- 9.31) , (22.34 +/- 10.15), (20.19 +/- 11.23) h, respectively. The NRS of pain was (4. 15 +/- 1.03), (3.26 +/- 1.17), (4.32 +/- 1.36), respectively. The duration time of pain was (4.05 +/- 1.21), (3.37 +/- 1.17), (3.19 +/- 1.67) d, respectively. In control group, the morbidity of phlebitis, the starting time of occurrence of phlebitis, the severity of pain, duration of pain was 24%, (17 +/- 6.32) h, (6.58 +/- 1.29), (5.32 +/- 1.12) d, respectively. As compared with the control group, a significance difference was found between every group in three test groups and control group respectively (P<0.05).
CONCLUSIONThe morbidity and the starting time of occurrence of phlebitis, the severity of pain, duration of pain was significantly reduced respectively by external appication of magnesium sulfate, anisodamine, and intravenous drip infusion of phentolaminum.
Adult ; Aged ; Aged, 80 and over ; Bufanolides ; adverse effects ; Female ; Humans ; Infusions, Intravenous ; Magnesium Sulfate ; therapeutic use ; Male ; Middle Aged ; Morbidity ; Phentolamine ; administration & dosage ; Phlebitis ; chemically induced ; prevention & control ; Solanaceous Alkaloids ; therapeutic use ; Time Factors

Result Analysis
Print
Save
E-mail